Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.

Anticancer research - 1 Jan 2000

Oikonomou Eftychia, Pintzas Alexandros

Abstract excerpt

Novel activating mutations in sporadic colorectal cancer (CRC) have recently been identified on major kinase encoding genes such as BRAF and PI3KCA. The presence of these activating point mutations, including the well characterized KRAS oncogene mutations, represent up to 75% of cases in CRC. These genes, that have been implicated in the adenoma-carcinoma transition, cause deregulation and constitutive activation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to BRAF gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Signal Transduction

Source

Identifiers

PMID: 16619509

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.PMID 16619509Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis.Semantic proximity Read ↗

The Landscape of PIK3CA Mutations in Colorectal Cancer.Semantic proximity Read ↗

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA MutationsSemantic proximity Read ↗

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.Semantic proximity Read ↗

Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status.Semantic proximity Read ↗

[Sporadic and hereditary colorectal cancer. Pathogenetically different with different therapeutic indications].Semantic proximity Read ↗

Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.Semantic proximity Read ↗

A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.Semantic proximity Read ↗

KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.